Skip to content
2000
Volume 22, Issue 5
  • ISSN: 1570-162X
  • E-ISSN: 1873-4251

Abstract

Introduction

People with the human immunodeficiency virus (PWH) who were diagnosed long ago are more prone to age-related conditions and comorbidities than the general population. We hypothesized that older PWH have endocrine abnormalities that may influence the patient’s health status.

Methods

Mean hormonal values across the thyrotropic, somatotropic, corticotropic, and gonadal axis, and percentage of subjects with abnormal values, were compared between PWH aged ≥50 years (n=30) and people without HIV (n=30) (Over50 cohort). Clinical factors were also analyzed as independent variables.

Results

PWH had a higher prevalence of comorbidities (36.67% PWH and 20.69% controls had ≥3 comorbidities). Male PWH exhibited lower estradiol levels than male controls (29.75±7.68 pg/mL . 35.45 ± 10.04 pg/mL; = 0.0041). Abnormal concentrations of testosterone were found in 35% of male PWH compared to 55% of male controls (mostly above reference values). Cortisol levels were significantly lower among PWH (9.97 ± 4.33 µg/dL . 13.56 ± 3.39 µg/dL; = 0.002); 16.6% of PWH exhibited abnormally low levels (<5 μg/dL), compared to 0% of controls, and 3 PWH met criteria for a definitive diagnosis of adrenal insufficiency (<3.6 μg/dL). For the somatotropic axis, growth hormone (GH) levels were significantly lower in male PWH than in controls ( = 0.0394). No significant differences were found in relation to the thyroid axis.

Conclusion

Hormones are generally similar between the chronic PWH who are receiving ART treatment and the general control population, except for cortisol in both sexes and testosterone and estradiol in men. Some special attention should be given to cortisol in PWH due to a presumably higher risk of adrenal complications.

Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X314729240822092738
2024-08-28
2025-01-25
Loading full text...

Full text loading...

References

  1. van den BeldA.W. KaufmanJ.M. ZillikensM.C. LambertsS.W.J. EganJ.M. van der LelyA.J. The physiology of endocrine systems with ageing.Lancet Diabetes Endocrinol.20186864765810.1016/S2213‑8587(18)30026‑330017799
    [Google Scholar]
  2. ZaidD. GreenmanY. Human immunodeficiency virus infection and the endocrine system.Endocrinol. Metab. (Seoul)20193429510510.3803/EnM.2019.34.2.9531257738
    [Google Scholar]
  3. MirzaF.S. LuthraP. ChirchL. Endocrinological aspects of HIV infection.J. Endocrinol. Invest.201841888189910.1007/s40618‑017‑0812‑x29313284
    [Google Scholar]
  4. NegredoE. LosteC. PuigJ. EcheverríaP. FumazC.R. Muñoz-MorenoJ.A. LemosB. MartínezA. TamayoF. SaizM. EstanyC. MatarrodonaM. BonjochA. BlancoN. SatorraP. ClotetB. Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged>70 years: a comparative cohort study (Over50 cohort).AIDS Care202234215516210.1080/09540121.2021.199831434743624
    [Google Scholar]
  5. RaghavanA. RimmelinD.E. FitchK.V. ZanniM.V. Sex differences in select non-communicable HIV-associated comorbidities: Exploring the role of systemic immune activation/inflammation.Curr. HIV/AIDS Rep.201714622022810.1007/s11904‑017‑0366‑829080122
    [Google Scholar]
  6. MilmanS. HuffmanD.M. BarzilaiN. The somatotropic axis in human aging: Framework for the current state of knowledge and future research.Cell Metab.201623698098910.1016/j.cmet.2016.05.01427304500
    [Google Scholar]
  7. StanleyT.L. FourmanL.T. WongL.P. SadreyevR. BillingsleyJ.M. FeldpauschM.N. ZhengI. PanC.S. BoutinA. LeeH. CoreyK.E. TorrianiM. KleinerD.E. ChungR.T. HadiganC.M. GrinspoonS.K. Growth hormone releasing hormone reduces circulating markers of immune activation in parallel with effects on hepatic immune pathways in individuals with HIV-infection and nonalcoholic fatty liver disease.Clin. Infect. Dis.202173462163010.1093/cid/ciab01933852720
    [Google Scholar]
  8. FourmanL.T. CzerwonkaN. ShaikhS.D. StanleyT.L. BurdoT.H. WilliamsK.C. FitchK.V. LoJ. GrinspoonS.K. Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV.AIDS201832792793229424780
    [Google Scholar]
  9. PattersonS MoranP EpelE Cortisol patterns are associated with T cell activation in HIV.PLoS One.201387e6342910.1371/journal.pone.0063429
    [Google Scholar]
  10. NorbiatoG. Endocrine, metabolic, and immunologic components of HIV infection.Ann. N. Y. Acad. Sci.201212621515510.1111/j.1749‑6632.2012.06620.x22823435
    [Google Scholar]
  11. AkaseI.E. HabibA.G. BakariA.G. MuhammadH. GezawaI. NashabaruI. IliyasuG. MohammedA.A. Occurrence of hypocortisolism in HIV patients: Is the picture changing?Ghana Med. J.201852314715210.4314/gmj.v52i3.730602800
    [Google Scholar]
  12. DuttaD. SharmaN. SharmaL.K. AnandA. GadpayleA.K. GauravK. MukherjeeS. KulshreshthaB. Presence, patterns & predictors of hypocortisolism in patients with HIV infection in India.Indian J. Med. Res.2018147214215010.4103/ijmr.IJMR_43_1629806602
    [Google Scholar]
  13. BornsteinS.R. AllolioB. ArltW. BarthelA. Don-WauchopeA. HammerG.D. HusebyeE.S. MerkeD.P. MuradM.H. StratakisC.A. TorpyD.J. Diagnosis and treatment of primary adrenal insufficiency: An endocrine society clinical practice guideline.J. Clin. Endocrinol. Metab.2016101236438910.1210/jc.2015‑171026760044
    [Google Scholar]
  14. Miguel NovoaP. VelaE.T. GarcíaN.P. RodríguezM.M. GuerrasI.S. Martínez de Salinas SantamaríaM.Á. MasóA.A. Guide for the diagnosis and treatment of adrenal insufficiency in adults.Endocrinol. Nutr.20146113510.1016/S1575‑0922(14)73526‑025128212
    [Google Scholar]
  15. NassoroD.D. MkhoiM.L. SabiI. MeremoA.J. LawalaP.S. MwakyulaI.H. Adrenal insufficiency: A forgotten diagnosis in HIV/AIDS patients in developing countries.Int J Endocrinol.20192019234285710.1155/2019/2342857
    [Google Scholar]
  16. SwannS.A. KingE.M. CôtéH.C.F. MurrayM.C.M. Stressing the need for validated measures of cortisol in HIV research: A scoping review.HIV Med.202223888089410.1111/hiv.1327235343039
    [Google Scholar]
  17. MadedduG. SpanuA. ChessaF. CaliaG.M. LoviguC. SolinasP. MannazzuM. FalchiA. MuraM.S. MadedduG. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.Clin. Endocrinol. (Oxf.)200664437538310.1111/j.1365‑2265.2006.02472.x16584508
    [Google Scholar]
  18. DevN. SahooR. KulshreshthaB. GadpayleA.K. SharmaS.C. Prevalence of thyroid dysfunction and its correlation with CD4 count in newly-diagnosed HIV-positive adults – a cross-sectional study.Int. J. STD AIDS2015261396597010.1177/095646241456377625505045
    [Google Scholar]
  19. ProperziM. della GiustinaT. MentastiS. CastelliF. ChiesaA. GregoriN. Quiros-RoldanE. Low prevalence of symptomatic thyroid diseases and thyroid cancers in HIV-infected patients.Sci. Rep.2019911945910.1038/s41598‑019‑56032‑731857648
    [Google Scholar]
  20. JiS. JinC. HöxtermannS. Prevalence and influencing factors of thyroid dysfunction in hiv-infected patients.Biomed Res Int.20162016387425710.1155/2016/3874257
    [Google Scholar]
  21. EmokpaeM.A. AkinnuoyeI.M. Asymptomatic thyroid dysfunction in human immunodeficiency virus-1-infected subjects.J. Lab. Physicians201810213013410.4103/JLP.JLP_172_1629692575
    [Google Scholar]
/content/journals/chr/10.2174/011570162X314729240822092738
Loading
/content/journals/chr/10.2174/011570162X314729240822092738
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publishers’ website along with the published article.

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test